A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

计划入组 732 人 · 首次发布于 2021 年 11 月 3 日

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

计划入组 60 人 · 首次发布于 2025 年 5 月 16 日

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

计划入组 30 人 · 首次发布于 2024 年 9 月 25 日

Tropinone

C₈H₁₃NO

micro-utropin

FlowVax BreastCA

Topcon

Trophos SA

France

TOPCON CORPORATION

Japan

Datopotamab Deruxtecan Fails to Meet Overall Survival Endpoint in TROPION-Breast01 Trial

FDA Accepts Datopotamab Deruxtecan BLA for HR-Positive, HER2-Negative Metastatic Breast Cancer

Datopotamab Deruxtecan's Role in HR+/HER2- Breast Cancer Treatment: Sequencing and Safety Considerations